The use of SGLT-2 inhibitors and hemoconcentration in patients with heart failure

11 May 2024 (08:00 - 20:00)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Hazal Unlugenc

Ege University Hospital, Izmir (Turkiye)

7 More presentations in this session

Presentation thumbnail

Quality of care among patients with heart failure with reduced ejection fraction at an outpatient setting in a tertiary center

Doctor K. Enriquez (Manila, PH)

Abstract Slides Video

Presentation thumbnail

The difference in the use of guideline-directed medical therapy in patients hospitalised for heart failure managed by cardiologists and non-cardiologists

Doctor T. Furlan (Trbovlje, SI)

Abstract Slides Video

Presentation thumbnail

Use of guideline-directed therapy in patients hospitalised at a general internal medicine ward

Doctor T. Furlan (Trbovlje, SI)

Abstract Slides Video

Presentation thumbnail

Did we forget ARNI in the era of SGLTi?

Doctor T. Cikara (Zagreb, HR)

Abstract Slides Video

Presentation thumbnail

Aspiring for precision: tailoring medication titration in heart failure patients

Doctor J. Santos Fonseca (Lisbon, PT)

Abstract Slides Video

Access the full session

Session thumbnail

ePosters in chronic heart failure - pharmacotherapy 2

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024

You may be interested in

Congress Presentation

Hematological outcomes of SGLT-2 inhibitors in heart failure patients: a systematic review and meta-analysis

Congress Presentation

Impact of SGLT2-inhibitors on cardiac function and structural changes in patients with heart failure and reduced ejection fraction - Results from the REWIN-HFrEF Study

Congress Presentation

Hemoglobin, hematocrit and heart failure: the SGLT2 inhibitor connection

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources